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B I O C H E M I S T R Y
Structure of the saxiphilin:saxitoxin (STX) complex 
reveals a convergent molecular recognition strategy for 
paralytic toxins
Tien-Jui Yen1, Marco Lolicato1, Rhiannon Thomas-Tran2*, J. Du Bois2, Daniel L. Minor Jr.1,3,4,5,6†
Dinoflagelates and cyanobacteria produce saxitoxin (STX), a lethal bis-guanidinium neurotoxin causing paralytic 
shellfish poisoning. A number of metazoans have soluble STX-binding proteins that may prevent STX intoxication. 
However, their STX molecular recognition mechanisms remain unknown. Here, we present structures of saxiphilin 
(Sxph), a bullfrog high-affinity STX-binding protein, alone and bound to STX. The structures reveal a novel high- 
affinity STX-binding site built from a “proto-pocket” on a transferrin scaffold that also bears thyroglobulin domain 
protease inhibitor repeats. Comparison of Sxph and voltage-gated sodium channel STX-binding sites reveals a con-
vergent toxin recognition strategy comprising a largely rigid binding site where acidic side chains and a cation- 
interaction engage STX. These studies reveal molecular rules for STX recognition, outline how a toxin-binding site 
can be built on a naïve scaffold, and open a path to developing protein sensors for environmental STX monitoring 
and new biologics for STX intoxication mitigation.
INTRODUCTION
Saxitoxin (STX), a bis-guanidinium small molecule produced by 
brackish and freshwater cyanobacteria and oceanic dinoflagelates 
associated with red tides, is one of the most lethal neurotoxins, causes 
paralytic shellfish poisoning (PSP), and is the only marine toxin that 
is declared a chemical weapon (1, 2). Its toxicity is thought to arise 
primarily from inhibition of select voltage-gated sodium channel 
(NaV) isoforms (3), although STX may affect other channels (4, 5) 
and enzymes (6). PSP caused by STX represents a notable public 
health and commercial hazard that is an increasing problem due to 
climate change (7). Consequently, shellfish for human consumption 
are monitored globally for PSP toxins. Current STX detection methods 
use a cumbersome mouse viability assay (8). Thus, there is great interest 
in developing better analytical techniques for measuring STX and 
related cogeners in food sources (7–9).
Nature uses diverse strategies to counter toxin exposure that in-
clude target protein resistance mutations, toxin sequestration, and 
toxin removal (10, 11). Although the best understood toxin resist-
ance strategies involve target protein mutations (10, 12, 13), frogs 
display unusual resistance to STX poisoning (14, 15) that is not be-
lieved to involve altered responses of frog NaVs to STX (16). Saxiphilin 
(Sxph), a 91-kDa transferrin homolog, is an STX-binding protein 
from American bullfrog (Rana catesbeiana) heart and plasma (16–20). 
This soluble, dual-function protein has a single high-affinity 
STX-binding site [Kd (dissociation constant), ~0.2 nM] that recog-
nizes certain STX derivatives (16, 21, 22) and has two ~60 residue 
thyroglobulin type I (Thy1) repeats (18) that act as potent [Ki (inhibi-
tion constant), ~1 nM] cysteine protease inhibitors (23). Other solu-
ble STX-binding proteins have been identified in pufferfish (24, 25), 
cockles (26), and crabs (27), and STX-binding activity has been 
reported in the plasma, hemolymph, and tissues from arthropods 
(19), amphibians (28), fish (19), and reptiles (19). Hence, it is thought 
that Sxph and analogous toxin-binding proteins constitute a second, 
less well-characterized toxin resistance mechanism involving toxin 
sequestration (10, 16, 19).
Here, we present high-resolution x-ray crystal structures of apo-
Sxph and STX-bound Sxph. These structures reveal key Sxph archi-
tectural features, how Sxph recognizes STX, and how the Thy1 domains 
may engage proteases. Remarkably, the two best-characterized high- 
affinity STX targets, Sxph and NaVs (29), share a core molecular 
recognition motif that defines a fingerprint for STX molecular 
recognition. This information should serve as a touchstone for un-
derstanding how STX interacts with channels and other targets (6) 
and provide guidance for the design of new molecular sensors for 
STX and related toxins.
RESULTS
Sxph crystal structure reveals a modified transferrin fold
The 2.5-Å resolution x-ray crystal structure of American bullfrog 
(R. catesbeiana) Sxph (Fig. 1A, fig. S1, A and B, and table S1) re-
vealed a bilobal organization similar to transferrins (30, 31), consist-
ing of an N-lobe (residues 1 to 88 and 232 to 465) and a C-lobe 
(residues 470 to 825) connected by a linker. Both lobes contain two 
subdomains, designated N1 (residues 1 to 88 and 389 to 465), N2 
(residues 232 to 388), C1 (residues 470 to 557 and 726 to 825), and 
C2 (residues 558 to 725). The N1 and C1 subdomains comprise dis-
continuous polypeptides into which N2 and C2 are inserted, respec-
tively (fig. S2). Unlike other transferrin family members, Sxph has a 
143-residue (residues 89 to 231) insertion between N1 and N2 that 
encodes two Thy1 repeats (fig. S2) (18, 23). The two Sxph protomers 
in the asymmetric unit are essentially identical except for a displace-
ment of the first thyroglobulin repeat by ~24° (fig. S1B). Hence, our 
description focuses on the more complete protomer B.
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The organization of the Sxph core architecture (N1, N2, C1, and 
C2) is conserved with transferrin (Fig. 1B). Sxph has 21 disulfides. 
Fourteen are conserved in the transferrin family. Seven are unique 
(Fig. 1C), of which five are in the Thy1 repeats (SS4 to SS8). The 
other two connect the 1N1 and 4N1 C-terminal ends (SS3) and 
the interdomain linker at the start of N2 to the C2 C-terminal tail 
(SS9) (Fig. 1C and fig. S2). The two Sxph lobes are related by a rigid 
body motion around the intersubdomain hinge that involves both 
a closure (~30°) and a twist (~60°) between the relatively closed 
(N-lobe) and open (C-lobe) conformations, respectively, (fig. S1C) 
that resembles the lobe conformations defined by apo- and Fe3+-
bound transferrin (32). Similar to other transferrin family structures, 
there is a small (558 Å2) mainly hydrophobic interface between 
N-lobe and C-lobe.
Consistent with the inability of Sxph to bind Fe3+ (18, 31), almost 
all of the residues in each lobe required to coordinate Fe3+ and an 
associated carbonate (33) differ substantially from the conserved 
transferrin ligands (Fig. 1B and fig. S3). There are also no interlobe 
-turns, a feature of all avian and mammalian transferrins that is 
thought to aid interlobe cleft opening for Fe3+ binding (32, 34). To-
gether, the structural data establish that Sxph has a transferrin-like 
fold having numerous modifications and demonstrate why Sxph lacks 
the classic transferrin Fe3+-binding function (35).
Sxph Thy1 repeats resemble Thy1 protease inhibitors
The ~60 residue thyroglobulin motif occurs in diverse proteins such 
as thyroglobulin, insulin-like growth factor–binding proteins, and 
the p41 invariant (Ii) chain involved in major histocompatibility 
Fig. 1. Sxph structure. (A) R. catesbeiana Sxph:STX: complex ribbon diagram. Domains are indicated and are colored as follows: N1 (smudge), N2 (limon), thyroglobulin 
(Thy; bright orange), C1 (marine), and C2 (cyan). STX (red) is shown as space filling. (B) Superposition of Sxph and rabbit transferrin [Protein Data Bank (PDB): 1JNF] (32). 
Transferrin N-lobe and C-lobe are colored purple and pink, respectively. Sxph Thy1 repeats are not shown. Insets show transferrin Fe3+ ligands and Sxph equivalents as 
sticks. N domain: transferrin (purple) and Sxph (green); C domain: transferrin (pink) and Sxph (blue). STX (red) is shown as space filling. Right hand inset shows distance 
between the STX center and transferrin Fe3+. (C) Cartoon diagram showing unique Sxph disulfide bonds in space filling representation: SS3 (Cys27 to Cys417) SS4 (Cys91 to 
Cys111), SS5 (Cys122 to Cys129), SS6 (Cys131 to Cys153), SS7 (Cys161 to Cys183), SS8 (Cys203 to Cys225), and SS9 (Cys234 to Cys825). Colors and labels are the same as in (A).
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complex class II maturation (36–39). The Sxph thyroglobulin do-
main forms an independent structure protruding from the N-lobe 
core (Fig. 1A). The two Thy1 repeats, Thy1-1 and Thy1-2 (Fig. 2A), 
adopt similar folds containing an -helix and two antiparallel 
-strands. Thy1-1 conforms to the Thy1 type 1A motif stabilized by 
three disulfides (40), whereas Thy1-2 lacks the inter–-strand di-
sulfide and conforms to the Thy1 type 1B motif (40). Both Sxph Thy1 
repeats have a wedge shape presenting three loops from one end 
and bear strong structural similarity to each other and the p41 Ii 
Thy1 repeat (Fig. 2B) (38).
Similar to p41 Ii, Sxph is a potent cysteine protease inhibitor, 
affecting cathepsin L, cathepsin B, and papain with nanomolar po-
tency (23). The two Thy1 repeats appear to enable Sxph to engage 
these targets with different stoichiometries (1:1 for cathepsin L and 
cathepsin B and 1:2 for papain) (23). Superposition of the p41:cathep-
sin L complex on the Thy1-1 and Thy1-2 domains (Fig. 2, C and D) 
indicates that the Thy1-1 repeat can bind the protease unhindered, 
whereas binding to Thy1-2 incurs clashes (Fig. 2D and fig. S4A). 
Superposition of papain, an enzyme very similar to cathepsin L but 
that Sxph binds with a 1:2 stoichiometry (23), shows similar clashes 
(fig. S4, A and B). Hence, it seems likely that local rearrangements 
mitigate these clashes. Comparison of the Sxph Thy1 domains with 
the p41:cathepsin L complex (38) highlights the features that likely 
contribute to Sxph Thy1 domain:protease interaction specificity (Fig. 2E). 
The conserved central Loop 2 (Fig. 2A) can be well positioned over 
the cathepsin L active site cysteine (Fig. 2E). Loop 3 of both repeats 
is longer than in p41 Ii (Fig. 2, A and B). However, this difference 
would not interfere with enzyme binding, as the p41 Loop 3 interac-
tions between Arg250 and the cathepsin L pocket lined by Trp189 and 
Trp193 are replaced by similar Sxph loop 3 tight turns in Thy1-1 and 
Fig. 2. Comparison of Sxph Thy1-1 and Thy1-2 with p41 Ii. (A) Sequence comparison. Thy1-1 and Thy1-2 secondary structure elements and disulfide bonds are indi-
cated. Cysteines and conserved residues are highlighted yellow and blue, respectively. (B) Cartoon diagram superposition of Thy1-1 (light orange), Thy1-2 (marine), and 
p41 Ii (magenta) (PDB: 1ICF) (38). Disulfide bonds (italics) and select residues are labeled. Thy1-1 and Thy1-2 have root mean square deviation of C position (RMSDC) = 0.61 
and 0.64 Å over 43 and 42 residues, respectively. p41 Ii has RMSDC = 0.57 Å over 53 residues of Sxph Thy1-1 and Thy1-2. (C and D) Superposition of Sxph on the p41 
Ii:cathespin L complex (PDB: 1ICF) (38) using the (C) Thy1-1 and (D) Thy1-2 domains. In (D), red oval indicates cathepsin L and Sxph C1 clash. Sxph colors are the same as 
in Fig. 1A. (E) Superposition of Sxph Thy1-1 (light orange), Thy1-2 (marine), and p41 Ii (magenta) in the context of the p41 Ii:cathepsin L interface.
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Thy1-2 (Fig. 2E). Loop 1 has the most varied conformations among 
Thy1 domains (fig. S4, C and D) and, in Thy1-1 and Thy1-2, has 
different mobilities, as Thy1-2 Loop 1 lacks visible electron density 
that indicates disorder. Comparison with the p41:cathepsin L com-
plex shows that Thy1-1 Loop 1 occupies the protease S2 pocket in a 
manner in which any observed clashes could be relieved by modest 
reorganization. Loop 1, the point of highest sequence divergence 
between Thy1-1 and Thy1-2 (Fig. 2A), is likely responsible for bind-
ing specificity differences. Together, these analyses indicate how 
variations in Thy1 Loop 3 can recognize a common target, support 
the role of Loop 1 in protease recognition specificity (40), and sug-
gest why Sxph binds similar proteases with different stoichiometries.
Structure of the Sxph:STX complex reveals a novel  
STX-binding site
Sxph binds STX with high affinity (Kd, 0.2 nM) and a 1:1 stoichiom-
etry (20). Crystals made by soaking apo-Sxph crystals with STX or 
by cocrystallization diffracted x-rays to 2.50- and 2.12-Å resolutions, 
respectively (table S1). The asymmetric units in both contained two 
essentially identical Sxph:STX complexes (root mean square devia-
tion of C position, 0.5 Å) that provide a high-resolution view of the 
Sxph:STX interaction (table S1). Because of its superior resolution 
and completeness, our description focuses on molecule B of the 
Sxph:STX cocrystallization complex.
Sxph and STX interact with a 1:1 stoichiometry matching bio-
chemical studies (16, 21). However, contrary to the idea that the STX- 
binding site is made by a remodeled Fe3+-binding cavity in the 
C1-C2 Sxph interdomain cleft (20), the Sxph:STX structure shows 
that a novel, solvent-exposed surface C1 pocket of ~14 Å away from 
the C1-C2 cleft forms the STX-binding site (Fig. 1A and figs. S1A 
and S5A) comprising C1 domain elements 3C1, 4C1, 6C1, and 
the 6C1-6C1 loop (Fig. 3A). Counter to previous proposals (20, 22), 
there are no large-scale conformational changes between apo-Sxph 
and Sxph:STX (fig. S5A). Hence, the Sxph:STX interaction occurs 
in an entirely unanticipated manner.
STX binds the STX pocket in an orientation in which its five- 
and six-membered guanidinium rings engage the protein, while the 
C12 hydrated ketone and carbamoyl group point toward solvent 
(Fig. 3, A to C, and fig. S5B). The STX pocket uses a set of charged 
side chains that directly engage the toxin together with contribu-
tions from backbone hydrogen bonding groups, van der Waals interac-
tions, and a cation- interaction (Fig. 3, A to C). A set of side chain 
carboxyls coordinate the five- and six-membered guanidinium rings 
engaging all available STX guanidinium nitrogen atoms. Asp785 and 
Asp794 form a network that encompasses the three nitrogen atoms 
of the guanidinium group on the five-membered ring (Fig. 3, A to C), 
whereas the Glu540 side chain interacts with both available six- 
membered ring guanidinium nitrogens (Fig. 3, A to C). This inti-
mate involvement of acidic side chains agrees with the observation 
that Sxph treatment with trimethyloxonium tetrafluorborate, a re-
agent that methylates aspartate and glutamate carboxylates, inhibits 
STX binding (20). Backbone carbonyl interactions from Asp785 with 
the five-membered ring N16 atom and Tyr795 with the six-membered 
ring N13 atom augment the side chain networks (Fig. 3C). Phe784 
forms the STX-binding pocket base and makes a cation- interac-
tion with the STX five-membered ring guanidinium (Fig. 3, B and C). 
Thus, rather than hydrophobic interactions as proposed (22), multiple 
sets of complimentary charged-based interactions comprise the 
Sxph:STX complex.
Although there are no large-scale changes between apo-Sxph and 
Sxph:STX (fig. S5A), some local rearrangements in the STX-binding 
pocket are evident from the initial difference maps (fig. S1A) and 
structure refinement. Asp785 shows the largest change and acts like 
a latch that faces away from the apo-Sxph pocket and that closes to 
interact with the STX N7 atom (Fig. 3, A and B, fig. S1A, and movie 
S1). The remaining changes involve a small movement of the Glu540 
away from the pocket and a ~15° rotation of the Tyr558 ring (Fig. 3B 
and movie S1). Hence, Sxph:STX high-affinity interaction results from 
capture of the rigid toxin by an essentially preformed binding site.
Radioligand competitive displacement studies of STX derivatives 
(fig. S5B) (19) match the observed binding pose and side chain in-
teractions. In line with the observation that STX carbamoyl moiety 
does not interact with Sxph, removal of this group (decarbamoyl 
STX; fig. S5B) or its modification with a sulfate (gonyautoxin V; fig. 
S5B) had only a ~2-fold and no impact on affinity, respectively (19). 
By contrast, hydroxylation of the six-membered ring N1 atom (neo-
saxitoxin; fig. S5B) reduced affinity by ~550-fold, supporting the 
importance of the interaction between N1 and Glu540. Further, sulfa-
tion of the C11 atom in the STX C1 derivative (fig. S5B) reduced 
binding relative to the STX B1 parent by ~150-fold, consistent with 
a clash between the sulfate and 6C1. The excellent agreement of 
these biochemical studies validates the observed binding pose and 
outlines how Sxph recognizes diverse naturally occurring STX 
derivatives.
STX-binding site elements are absent from transferrins and 
Sxph N-lobe
Transferrins do not bind STX (35), and the STX-binding pocket re-
sides in a region that has not been reported to bind small molecules 
in other transferrin family members. How then did nature sculpt the 
STX-binding pocket from a naïve transferrin scaffold? Comparison 
of Sxph with two exemplar transferrins, Fe3+-bound rabbit serum 
transferrin [Protein Data Bank (PDB): 1JNF] (41) (Fig. 4A) and apo- 
human serum transferrin (PDB: 2HAU) (32) (Fig. 4B), reveals a 
shallow “proto-pocket” on the transferrin C1 subdomain surface at the 
location of the STX-binding site. Notably, the structural homologs 
of the residues that form Sxph:STX interactions differ considerably 
(fig. S3). In the transferrins, positively charged and small hydrophobic 
residues are found at the positions of the Sxph acidic residues that 
coordinate the STX five-membered (Asp785 and Asp794) and six- 
membered (Glu540) rings, respectively. Further, residues corresponding 
to Phe784, the amino acid responsible for the cation- interaction, 
are all branched, hydrophobic residues incapable of making this type 
of interaction.
Besides lacking the residues to coordinate STX, the rather shal-
low transferrin C1 proto-pocket is too small to accommodate a 
molecule the size of STX. Structural comparisons highlight changes 
in Spxh elements on opposite sides of the pocket that expand its size 
(Fig. 4, C to E). Namely, the Sxph 6C1 helix position differs from 
the corresponding transferrin helices (residues 643 to 648 and 646 
to 650 in rabbit and human transferrin, respectively; Fig. 4, A and B), 
and the loop adjacent to the STX carbamate (residues 555 to 561) 
differs relative to the corresponding transferrin structure (residues 
418 to 423 and 419 to 424 in rabbit and human transferrin, respec-
tively; Fig. 4, A and B). This Sxph loop is buttressed by the 4C1 
helix, which is absent in transferrin (Fig. 4, A and B, and fig. S3). 
Collectively, these changes create a site ringed by a set of negatively 
charged atoms that complement the dicationic STX (Fig. 4E).
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Sxph N1 and C1 are structurally similar (fig. S6A), and N1 has a 
proto-pocket that corresponds to the C1 STX-binding site. This 
proto-pocket is more open than in the transferrins and is framed on 
one side by two helices, 5N1 and 6N1, that match the C1 domain 
6C1 and 7C1 (fig. S6B). However, 6N1 and Tyr82 on the opposite 
side of the narrow N1 proto-pocket would clash with the toxin near 
the C12 hemiketal and C13 carbamate, respectively (fig. S6A). Most 
importantly, Sxph N1 lacks residues that could coordinate STX. The 
C1 residues that engage the two guanidinium rings, Glu540, Asp794, 
Asp785, and Phe784, are replaced in N1 by Ala79, Leu448, Ser441, and 
Leu440, respectively, rendering the site incapable of making the 
necessary electrostatic and cation- interactions (fig. S6A). Further, 
the N1 proto-pocket is occluded by 8C1, 7C1, and 5T (fig. S6C). 
Hence, a multitude of factors prevents Sxph from using the N1 sub-
domain proto-pocket as a second STX-binding site.
A frog Sxph homolog has the STX-binding motif
Although other STX-binding proteins have been reported (24–27), 
none are related to Sxph. We identified Sxph-like sequences in an 
invertebrate, springtail (Folsomia candida); two fish, Nile tilapia 
(Oreochromis niloticus) and Northern pike (Esox lucius); and the High 
Himalaya frog (Nanorana parkeri) (fig. S7). All share the transferrin 
fold core with Sxph and carry mutations that would prevent Fe3+ 
binding. The springtail and High Himalaya frog sequences also have 
two Thy1 repeat insertions between the N1 and N2, making them 
closer homologs to Sxph than the fish sequences. Notably, the High 
Himalaya frog sequence has the key features for STX recognition, 
namely, C1 equivalents of Glu540, Asp785, Asp794, and Phe784 that 
match the STX recognition fingerprint. Hence, bullfrog Sxph is not 
unique and has a counterpart in a frog from a distantly related family 
(Dicroglossidae) that we name SxphNP.
Sxph and NaVs recognize STX using a similar molecular logic
NaVs are the primary target for the paralytic effects of STX and bind 
STX with nanomolar affinity, similar to Sxph (1, 20). To ask whether 
NaVs and Sxph use a common STX recognition strategy, we compared 
structures of the STX-binding sites of Sxph and the cockroach NaV 
NaVPaS:STX complex determined at 3.2-Å resolution by single-particle 
cryo-electronmicroscopy (cryo-EM; Fig. 5, A and B) (29). Although 
the two proteins are unrelated and some recognition details appear 
to differ, namely, at the site of the hydrated C12 ketone (29, 42, 43), 
there are remarkably common STX molecular recognition themes. 
The channel and Sxph both engage the five- and six-membered 
guanidinium rings using side chain carboxylates. NaVPaS Glu378 
recognizes the five-membered ring similar to Sxph Asp794, and NaVPaS 
Glu704 coordinates the two available nitrogens of the six-membered 
guanidinium similar to Sxph Glu540 (Fig. 5, C and D, and fig. S8A). 
Both glutamates are important for the NaV:STX interaction (44, 45). 
The two proteins also use an aromatic ring to engage the STX concave 
face through a cation- interaction; however, the recognized STX ring 
differs. NaVPaS Tyr376, a residue important for STX binding (45, 46), 
engages the STX six-membered ring, whereas Sxph Phe784 interacts 
Fig. 3. Sxph STX-binding site. (A) Apo-Sxph (olive) and STX-bound Sxph (slate) superposition cartoon diagram. STX-interacting residues are shown as sticks. Key secondary 
structure elements are labeled. Black and gray dashed lines indicate hydrogen bond networks and the cation- interaction, respectively. STX is shown as red sticks. Gdm-5, 
Gdm-6, and HK indicate the five- and six-membered guanidinium rings and hemiketal, respectively. (B) STX-binding site highlighting the cation- interaction (gray) and 
Asp785 movement. (C) LIGPLOT diagram of the STX-binding site. 6C1 is shown for orientation.
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with the five-membered ring (fig. S8B). Similar interactions are found in 
the recent 3.2-Å cryo-EM structure of a human NaV1.7:STX complex 
(Fig. 5E and fig. S8, B to D) (47). Although the resolutions of the 
NaVPaS:STX and NaV1.7:STX structures and issues regarding acidic 
side chain definition by cryo-EM relative to x-ray studies (48–50) place 
limits on a very detailed comparison of STX binding, it is obvious that 
the two completely unrelated proteins, Sxph and NaVs, share general 
STX recognition rules (Fig. 5E).
DISCUSSION
The Sxph structure defines a paradigm for molecular recognition of 
STX, one of nature’s most lethal poisons (1, 3, 6) at atomic resolu-
tion. The Sxph core is built from the transferrin fold (Fig. 1B), a family 
of soluble proteins best known for Fe3+ transport (30, 31), that has 
been modified to act as a “dual-function” protein that can make high- 
affinity interactions with STX and cysteine proteases. Contrary to 
expectations (20), the STX-binding site is not a remodeled version of 
the Fe3+-binding site but resides at a unique locale on the C1 domain. 
This high-affinity binding site undergoes minimal conformational 
changes upon binding the rigid STX scaffold. Remarkably, the general 
blueprint for STX recognition by Sxph using side chain carboxylates, a 
cation- interaction, and a largely rigid binding site is shared with NaVs 
(1, 13, 29, 44–47). This commonality between a 91-kDa soluble pro-
tein and a ~200-kDa membrane protein ion channel unmasks an 
extraordinary convergence of STX molecular recognition strategies.
Fig. 4. Sxph STX-binding site and transferrin proto-pocket. (A and B) Superposition of the Sxph (marine) STX-binding site with (A) Fe3+-bound rabbit serum transferrin 
(PDB: 1JNF) (41) (pink) and (B) apo-human serum transferrin (PDB: 2HAU) (32) (gray). STX (red) is shown as sticks. Select residues are shown. Blue labels indicate Sxph residues. 
Orange arrows indicate changes between transferrin and Sxph. (C to E) Transferrin proto-pocket and Sxph STX-binding pocket comparisons. (C) to (E) show apo-transferrin 
(pink), transferrin (gray), and Sxph (marine) surfaces, respectively. In (C) and (D), labels indicate Sxph residues that break through the transferrin surface. Red circle highlights 
the STX-binding site. STX is shown as space filling. Sxph surface is colored by atom type, where red and blue denote oxygen and nitrogen, respectively.
Yen et al., Sci. Adv. 2019; 5 : eaax2650     19 June 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
7 of 10
How proteins acquire new ligand-binding sites is an unresolved 
question for which surface pockets are thought to be a key factor 
(51, 52). Transferrins do not bind STX (35). Structural comparisons 
of Sxph and transferrins identify a transferrin proto-pocket at cognate 
position of the Sxph STX-binding site. This region is not known to 
bind small molecules in any transferrin family member. Nevertheless, 
the structural data suggest that a limited set of changes are required 
to reshape this naïve site into a high-affinity small-molecule bind-
ing site and provide an example of how a protein scaffold can acquire 
a new function.
Organisms are thought to cope with toxin exposure through di-
verse strategies that include target protein resistance mutations, 
toxin sequestration, and toxin removal (10, 11). Frogs are resistant 
to STX (14, 15), and Sxph may contribute to this property (16, 19). 
Although how toxin target mutations confer toxin resistance has 
been widely studied (12, 13, 53), understanding of alternative resist-
ance mechanisms remains primitive. Our findings provide the first 
structural characterization of a toxin “molecular sponge,” identify 
an Sxph candidate in a distantly related frog family (Raindae versus 
Dicroglossidae), and provide a starting point for molecular dissection 
Fig. 5. Sxph and NaVs share STX recognition strategies. (A) NaVPaS:STX (PDB: 6a91) (29) and Sxph:STX STX-binding site superposition. NaVPaS is shown as a cartoon viewed 
from the central channel cavity. Pore domains are colored as follows: DI, green; DII, orange; DIII, yellow; and DIV, pink. STX coordinating and selectivity filter “DEKA” motif (white) 
residues are shown as sticks. Sxph STX-binding site side chains are blue. STX from Sxph:STX (red) and NaVPaS:STX (cyan) are superposed. (B) Closeup view of the STX-binding 
sites from (A). (C) Diagram of the NaVPaS:STX interactions. (D) Diagram of the Sxph:STX interactions. (E) Comparison of common STX interactions for Sxph (blue), NaVPaS (green), 
and NaV1.7 (magenta). STX from the Sxph:STX complex (red), NaVPaS:STX complex (cyan), and NaV1.7:STX complex (violet) are indicated. (C) and (D) were generated using 
LIGPLOT (67) and a 3.35-Å cutoff. Hydrogen bonding networks (black dashed lines) and cation- interactions (gray dashed lines) are indicated. (D) is the same as Fig. 3C.
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of toxin sequestration mechanisms. The observation that other orga-
nisms have soluble STX-binding proteins unrelated to Sxph (24–28) 
indicates that toxin sequestration is a general strategy (10, 16, 19) and 
that de novo STX-binding site creation has happened multiple times.
Defining how proteins recognize STX has implications for 
understanding its lethal effects, the mechanisms by which organisms 
evade intoxication, and the design of sensors that could monitor PSP 
toxins in the environment and food. The Sxph:STX complex struc-
ture defined here offers a new path to design protein-based assays 
for STX and related toxins (7–9, 54), provides a blueprint for STX 
target identification, and should aid development of STX intoxication 
countermeasures.
MATERIALS AND METHODS
Protein expression and purification
The gene for North American bullfrog, R. catesbeiana, Sxph (GenBank: 
U05246.1), including its N-terminal secretory sequence, was codon- 
optimized and synthesized by GenScript. The Sxph gene was cloned 
into the BamHI and HindIII multiple cloning sites of pFastBac1 
(Invitrogen) in frame with a C-terminal 3C protease cleavage site, 
followed by green fluorescent protein (GFP) and a His10 tag. Bacmids 
and baculovirus were generated following the manufacturer’s pro-
tocol (Bac-to-Bac, Invitrogen). P2 baculovirus was used for trans-
duction at dilution of 1:40 into Sf9 cells at cell density of 2 × 106 cells 
ml−1 in ESF921 media (Expression Systems). Cells were grown for 
72 hours after transduction, and the expressed Sxph-GFP fusion 
protein was secreted into the growth media. Cells were removed by 
centrifugation, and the supernatant was adjusted to pH 8.0 with a 
final concentration of 50 mM Tris-HCl and treated with 1 mM NiCl2 
and 5 mM CaCl2 to precipitate contaminants. Precipitants were re-
moved by centrifugation, and the clarified supernatant was incubated 
with anti-GFP nanobody-conjugated sepharose beads (55, 56) for 
5 hours at room temperature. Beads were washed with 20 column 
volumes of a buffer containing 300 mM NaCl and 30 mM Tris-HCl 
(pH 7.4). On-column cleavage of the GFP-His tag was achieved by 
incubating with 3C protease (0.1 mg ml−1) (57) overnight at 4°C.
Cleaved sample was further purified by size exclusion chroma-
tography using a Superdex 200 10/300 GL column in buffer 
containing 150 mM NaCl and 10 mM HEPES (pH 7.4).
Crystallization and structure determination
Purified Sxph was exchanged into a buffer of 10 mM NaCl and 
10 mM HEPES (pH 7.4) and then concentrated to 65 mg ml−1 using 
a 50-kDa molecular weight cutoff Amicon Ultra centrifugal filter 
(Millipore) for crystallization screening by hanging drop vapor diffu-
sion at 4°C using a 2:1 ratio of protein to screening solution. Apo-Sxph 
was crystallized from solution containing 0.1 M sodium cacodylate 
(pH 6.5), 5% PEG 8000, and 40% 2-methyl-2,4-pentanediol. Addi-
tion of 0.5% -dodecyl maltoside or 10 mM sodium bromide to the 
crystallization solution further improved crystal quality of apo-Sxph. 
Crystals of the Sxph:STX complex were obtained by soaking STX 
(final concentration, 1 mM) into apo crystals for 5 hours before 
freezing. For cocrystallization, STX was added to Sxph in a molar 
ratio of 1.1:1 STX:Sxph. The sample was then incubated on ice for 
1 hour before setting up crystallization. X-ray datasets for apo-Sxph 
and the Sxph:STX complex were collected at Advanced Light Source 
beamline 8.3.1 (Berkeley, CA) processed with XDS (58) and scaled 
and merged with Aimless (59). The apo-Sxph structure was deter-
mined by molecular replacement using Phaser from PHENIX (60) 
and the N-lobe of human serum transferrin (PDB: 1D4N) (61) as a 
search model. The resulting electron density map was further im-
proved by rigid body refinement using phenix.refine and density 
modification using RESOLVE (62). The placed starting model was 
then subjected to model morphing in PHENIX using the prime-
and-switch map generated from density modification (63). The mor-
phed model thus allowed subsequent manual model building into 
the prime-and-switch map in COOT (64). Iterative model building, 
refinement, density modification, and model morphing allowed the 
apo-Sxph N-lobe and C1 domain to be built and refined (R-free of 
31.7%) but left poor-quality electron density for the entire C2 do-
main. The feature-enhanced map (FEM) option (65) was applied in 
PHENIX to aid model building of the Sxph C2 domain. The C2 
domain of rabbit serum transferrin (PDB: 1JNF) (41) was used as a 
starting model and placed into the FEM by rigid-body fitting. Sub-
sequent model rebuilding and refinement were performed in COOT 
(64) and phenix.refine (60). The structure of the Sxph:STX complex 
was determined by molecular replacement using apo-Sxph as the 
search model in Phaser (60). Model building and refinement were 
carried out using COOT (64) and phenix.refine (60).
STX synthesis
STX was synthesized, purified, and validated as described in (66).
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